ESTRO 2022 - Abstract Book

S1648

Abstract book

ESTRO 2022

in overall volume irradiated of 37.1% (min 32.4% and max 39.9%)(Table 2) . For both the original fractionation schedule and the new schedule organ-at-risk (OAR) toxicity was within tolerance.

Conclusion This pilot study demonstrates that data using the RayPilot ® device it is possible monitor intra-fraction motion and as a result reduce treatment margins and subsequently SBRT fractions. However, analysis is required on a much larger cohort before any reduction in margins can be recommended.

PO-1858 Patient recruitment by RTTs yields high accrual in a randomized trial of palliative radiotherapy.

A.C. Lund 1 , A.M. Nielsen 2 , A. Caranovic 3 , J. Friborg 1 , V.N. Hansen 1 , T.S. Johansen 1 , B.S. Kristensen 1 , R. Marseguerra 1 , K.N. Matthiesen 1 , L. Prenter 1 , D.A. Schut 1 , S.E. Tvile 1 , A. Munk 1 , D. Sørensen 1 , A. Green 1 , M. Langballe 4 , T.R.B. Jensen 1 , A.F. Fastø 1 , L. Aalund 1 , G.F. Persson 5 , I.R. Vogelius 1 , M.H. Suppli 1 1 Rigshospitalet, University of Copenhagen, Dept. of Oncology, Copenhagen, Denmark; 2 Herlev-Gentofte Hospital, University of Copenhagen, Herlev, Dept. of Oncology, Herlev, Denmark; 3 Rigshospitalet, University of Copenhagen , Dept. of Oncology, Copenhagen, Denmark; 4 Rigshospitalet, University of Copenhagen, Dept. of Oncology, Copenhagen,, Denmark; 5 Herlev-Gentofte Hospital, University of Copenhagen, Dept. Of Oncology, Herlev, Denmark Purpose or Objective The ESO-SPARE randomized trial compares esophagus-sparing radiotherapy to standard IMRT for palliation of metastatic spinal cord compression. See Figure 1 for trial dose planning examples. Primary endpoints are patient reported gastro- esophageal toxicity and preservation of ability to walk. Sample size is 2x100 patients to be accrued in two hospitals. We aim to facilitate a high accrual rate through integration with the clinical functions in a pragmatic trial setup driven by RTTs.

Materials and Methods